GETI.B

209.1

+1.7%↑

CAMX

609

+2.78%↑

BIOAB

320.6

+1.84%↑

EKTA.B

55.85

+3.04%↑

VITR

138.6

+0.36%↑

GETI.B

209.1

+1.7%↑

CAMX

609

+2.78%↑

BIOAB

320.6

+1.84%↑

EKTA.B

55.85

+3.04%↑

VITR

138.6

+0.36%↑

GETI.B

209.1

+1.7%↑

CAMX

609

+2.78%↑

BIOAB

320.6

+1.84%↑

EKTA.B

55.85

+3.04%↑

VITR

138.6

+0.36%↑

GETI.B

209.1

+1.7%↑

CAMX

609

+2.78%↑

BIOAB

320.6

+1.84%↑

EKTA.B

55.85

+3.04%↑

VITR

138.6

+0.36%↑

GETI.B

209.1

+1.7%↑

CAMX

609

+2.78%↑

BIOAB

320.6

+1.84%↑

EKTA.B

55.85

+3.04%↑

VITR

138.6

+0.36%↑

Home・Aandelen Lijst・Orexo AB

O
Orexo AB

Gesloten

23.85 0.85

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

23.6

Max

24.3

Belangrijke statistieken
By Trading Economics
Inkomsten	-26M -48M
Verkoop	500K 119M
EPS	-0.859
Winstmarge	-40.27
Werknemers	104
EBITDA	300K -9.8M

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-73M 857M
Vorige openingsprijs	23
Vorige sluitingsprijs	23.85

Orexo AB Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 dec 2025, 22:02 UTC

Winsten

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 dec 2025, 21:46 UTC

Winsten

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 dec 2025, 23:52 UTC

Acquisities, Fusies, Overnames

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 dec 2025, 23:43 UTC

Marktinformatie

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 dec 2025, 23:36 UTC

Marktinformatie

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 dec 2025, 23:20 UTC

Winsten

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 dec 2025, 23:15 UTC

Winsten

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 dec 2025, 22:59 UTC

Marktinformatie

Winsten

Acquisities, Fusies, Overnames

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 dec 2025, 22:45 UTC

Marktinformatie

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 dec 2025, 22:40 UTC

Winsten

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dec 2025, 22:06 UTC

Acquisities, Fusies, Overnames

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dec 2025, 22:06 UTC

Winsten

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dec 2025, 22:02 UTC

Winsten

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dec 2025, 22:00 UTC

Winsten

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 dec 2025, 21:53 UTC

Winsten

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dec 2025, 21:50 UTC

Acquisities, Fusies, Overnames

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 dec 2025, 21:50 UTC

Marktinformatie

Winsten

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

10 dec 2025, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

10 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

10 dec 2025, 21:45 UTC

Acquisities, Fusies, Overnames

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dec 2025, 21:33 UTC

Winsten

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 dec 2025, 21:32 UTC

Winsten

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 dec 2025, 21:25 UTC

Winsten

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dec 2025, 21:18 UTC

Acquisities, Fusies, Overnames

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 dec 2025, 21:16 UTC

Winsten

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 dec 2025, 21:15 UTC

Acquisities, Fusies, Overnames

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 dec 2025, 21:15 UTC

Winsten

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 dec 2025, 21:14 UTC

Winsten

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 dec 2025, 21:14 UTC

Winsten

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Peer Vergelijking

Prijswijziging

Orexo AB Prognose

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Orexo AB

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.